Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection
Aims: To determine the visual outcome following initiation of brimonidine therapy in glaucoma. Methods: 16 newly diagnosed previously untreated glaucoma patients were randomly assigned to either timolol 0.5% or brimonidine 0.2%. Visual acuity, contrast sensitivity (CS), visual fields, intraocular pr...
Saved in:
Published in | British journal of ophthalmology Vol. 87; no. 12; pp. 1463 - 1465 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
BMA House, Tavistock Square, London, WC1H 9JR
BMJ Publishing Group Ltd
01.12.2003
BMJ BMJ Publishing Group LTD Copyright 2003 British Journal of Ophthalmology |
Subjects | |
Online Access | Get full text |
ISSN | 0007-1161 1468-2079 |
DOI | 10.1136/bjo.87.12.1463 |
Cover
Abstract | Aims: To determine the visual outcome following initiation of brimonidine therapy in glaucoma. Methods: 16 newly diagnosed previously untreated glaucoma patients were randomly assigned to either timolol 0.5% or brimonidine 0.2%. Visual acuity, contrast sensitivity (CS), visual fields, intraocular pressure (IOP), blood pressure, and heart rate were evaluated at baseline and after 3 months. Results: IOP reduction was similar for both groups (p<0.05). Brimonidine improved CS; in the right eye at 6 and 12 cpd (p = 0.043, p = 0.017); in the left eye at 3 and 12 cpd (p = 0.044, p = 0.046). Timolol reduced CS at 18 cpd in the right eye (p = 0.041). There was no change in any other measured parameters. Conclusion: Glaucoma patients exhibit improved CS on initiation of brimonidine therapy. |
---|---|
AbstractList | Aims: To determine the visual outcome following initiation of brimonidine therapy in glaucoma. Methods: 16 newly diagnosed previously untreated glaucoma patients were randomly assigned to either timolol 0.5% or brimonidine 0.2%. Visual acuity, contrast sensitivity (CS), visual fields, intraocular pressure (IOP), blood pressure, and heart rate were evaluated at baseline and after 3 months. Results: IOP reduction was similar for both groups (p<0.05). Brimonidine improved CS; in the right eye at 6 and 12 cpd (p = 0.043, p = 0.017); in the left eye at 3 and 12 cpd (p = 0.044, p = 0.046). Timolol reduced CS at 18 cpd in the right eye (p = 0.041). There was no change in any other measured parameters. Conclusion: Glaucoma patients exhibit improved CS on initiation of brimonidine therapy. To determine the visual outcome following initiation of brimonidine therapy in glaucoma.AIMSTo determine the visual outcome following initiation of brimonidine therapy in glaucoma.16 newly diagnosed previously untreated glaucoma patients were randomly assigned to either timolol 0.5% or brimonidine 0.2%. Visual acuity, contrast sensitivity (CS), visual fields, intraocular pressure (IOP), blood pressure, and heart rate were evaluated at baseline and after 3 months.METHODS16 newly diagnosed previously untreated glaucoma patients were randomly assigned to either timolol 0.5% or brimonidine 0.2%. Visual acuity, contrast sensitivity (CS), visual fields, intraocular pressure (IOP), blood pressure, and heart rate were evaluated at baseline and after 3 months.IOP reduction was similar for both groups (p<0.05). Brimonidine improved CS; in the right eye at 6 and 12 cpd (p=0.043, p=0.017); in the left eye at 3 and 12 cpd (p=0.044, p=0.046). Timolol reduced CS at 18 cpd in the right eye (p=0.041). There was no change in any other measured parameters.RESULTSIOP reduction was similar for both groups (p<0.05). Brimonidine improved CS; in the right eye at 6 and 12 cpd (p=0.043, p=0.017); in the left eye at 3 and 12 cpd (p=0.044, p=0.046). Timolol reduced CS at 18 cpd in the right eye (p=0.041). There was no change in any other measured parameters.Glaucoma patients exhibit improved CS on initiation of brimonidine therapy.CONCLUSIONGlaucoma patients exhibit improved CS on initiation of brimonidine therapy. Aims: To determine the visual outcome following initiation of brimonidine therapy in glaucoma. Methods: 16 newly diagnosed previously untreated glaucoma patients were randomly assigned to either timolol 0.5% or brimonidine 0.2%. Visual acuity, contrast sensitivity (CS), visual fields, intraocular pressure (IOP), blood pressure, and heart rate were evaluated at baseline and after 3 months. Results: IOP reduction was similar for both groups (p<0.05). Brimonidine improved CS; in the right eye at 6 and 12 cpd (p = 0.043, p = 0.017); in the left eye at 3 and 12 cpd (p = 0.044, p = 0.046). Timolol reduced CS at 18 cpd in the right eye (p = 0.041). There was no change in any other measured parameters. Conclusion: Glaucoma patients exhibit improved CS on initiation of brimonidine therapy. To determine the visual outcome following initiation of brimonidine therapy in glaucoma. 16 newly diagnosed previously untreated glaucoma patients were randomly assigned to either timolol 0.5% or brimonidine 0.2%. Visual acuity, contrast sensitivity (CS), visual fields, intraocular pressure (IOP), blood pressure, and heart rate were evaluated at baseline and after 3 months. IOP reduction was similar for both groups (p<0.05). Brimonidine improved CS; in the right eye at 6 and 12 cpd (p=0.043, p=0.017); in the left eye at 3 and 12 cpd (p=0.044, p=0.046). Timolol reduced CS at 18 cpd in the right eye (p=0.041). There was no change in any other measured parameters. Glaucoma patients exhibit improved CS on initiation of brimonidine therapy. |
Audience | Professional Academic |
Author | Hosking, S L Bartlett, J D Evans, D W Gherghel, D |
AuthorAffiliation | 1 School of Optometry, University of Alabama at Birmingham, Birmingham, AL, USA 2 Neuroscience Research Institute, Aston University, Aston Triangle, Birmingham B4 7ET, UK 3 School of Optometry, University of Alabama at Birmingham, and Department of Pharmacology and Toxicology, School of Medicine, University of Alabama, Birmingham, AL, USA |
AuthorAffiliation_xml | – name: 3 School of Optometry, University of Alabama at Birmingham, and Department of Pharmacology and Toxicology, School of Medicine, University of Alabama, Birmingham, AL, USA – name: 1 School of Optometry, University of Alabama at Birmingham, Birmingham, AL, USA – name: 2 Neuroscience Research Institute, Aston University, Aston Triangle, Birmingham B4 7ET, UK |
Author_xml | – sequence: 1 givenname: D W surname: Evans fullname: Evans, D W organization: School of Optometry, University of Alabama at Birmingham, and Department of Pharmacology and Toxicology, School of Medicine, University of Alabama, Birmingham, AL, USA – sequence: 2 givenname: S L surname: Hosking fullname: Hosking, S L organization: School of Optometry, University of Alabama at Birmingham, and Department of Pharmacology and Toxicology, School of Medicine, University of Alabama, Birmingham, AL, USA – sequence: 3 givenname: D surname: Gherghel fullname: Gherghel, D organization: School of Optometry, University of Alabama at Birmingham, and Department of Pharmacology and Toxicology, School of Medicine, University of Alabama, Birmingham, AL, USA – sequence: 4 givenname: J D surname: Bartlett fullname: Bartlett, J D organization: School of Optometry, University of Alabama at Birmingham, and Department of Pharmacology and Toxicology, School of Medicine, University of Alabama, Birmingham, AL, USA |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15811123$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/14660453$$D View this record in MEDLINE/PubMed |
BookMark | eNqFksuLFDEQhxtZcR969SgBUfDQYx7TSdqDsAzurrDoxccxpNOV2YzdyZhkBve_N82MsyorkkORyle_euW0OvLBQ1U9JXhGCOOvu1WYSTEjdEbmnD2oToqRNcWiPapOMMaiJoST4-o0pVW5Uk7Eo-q4QBzPG3ZSxUXwOeqUUQKfXHZbl2-RG9cxbCEhbTNE1EU3Bu965wHlG4h6XRCP1sWt4y0Ka_BI--UAaDnojQmjfoM0MjoBsiEiD5sYimAGk13wj6uHVg8JnuztWfX54t2nxVV9_fHy_eL8uu6aluW6J0B5b0wP2jDbWNtg2pumbxkxgko7xxIaEMxKyjuqeddqDY3ktO9aa4VkZ9Xbne56043QG5gaHdS-ahW0U3--eHejlmGrSEtxI3gReLkXiOH7BlJWo0sGhkF7CJukBJkzLltSwOd_gauwib40p4gQssVMyEmu3lFLPYBy3oaS1SzBl4EOZavWFfc5IaQVhDNc-Nk9fDk9jM7cG_Ds94YPnf7adgFe7AGdjB5s1N64dMc1sojRiZvvOBNDShGsMi7raXelAjcogtX0-VT5fEoKReiUgt0VfAg7KP8rYD8RlzL8ONA6flNcMNGoD18WSlwuvnIsrtRF4V_t-G5c_U_7J6dQ-mc |
CODEN | BJOPAL |
CitedBy_id | crossref_primary_10_1016_j_exer_2006_10_002 crossref_primary_10_1016_j_ophtha_2014_04_014 crossref_primary_10_1016_j_ajo_2005_03_058 crossref_primary_10_1038_eye_2008_226 crossref_primary_10_4103_ijo_IJO_1158_21 crossref_primary_10_4103_meajo_MEAJO_259_17 crossref_primary_10_56951_medicinus_v36i2_119 crossref_primary_10_1038_s41433_022_02305_x crossref_primary_10_4236_ojoph_2012_23013 crossref_primary_10_1016_j_preteyeres_2024_101261 crossref_primary_10_1093_ageing_afp259 crossref_primary_10_1111_j_1442_9071_2008_01720_x crossref_primary_10_1111_j_1442_9071_2009_02108_x crossref_primary_10_3233_JAD_220016 crossref_primary_10_1016_j_preteyeres_2018_04_001 crossref_primary_10_1111_ceo_13818 crossref_primary_10_1089_jop_2007_0106 crossref_primary_10_21516_2072_0076_2023_16_4_147_151 crossref_primary_10_1089_jop_2007_0127 crossref_primary_10_1016_j_ophtha_2013_12_011 crossref_primary_10_1016_j_ajo_2020_04_032 crossref_primary_10_1089_jop_2011_0014 crossref_primary_10_1111_j_1755_3768_2011_02130_x crossref_primary_10_1155_2017_4586763 crossref_primary_10_1089_jop_2007_0022 crossref_primary_10_1007_s00417_005_1160_7 crossref_primary_10_1089_jop_2005_21_475 crossref_primary_10_1111_ceo_14120 crossref_primary_10_1002_14651858_CD006539_pub4 crossref_primary_10_1016_j_survophthal_2020_12_004 crossref_primary_10_17116_oftalma2019135031113 crossref_primary_10_2147_OPTH_S369626 crossref_primary_10_3390_cells9122594 crossref_primary_10_3390_ph17101261 crossref_primary_10_1586_eop_10_69 crossref_primary_10_3390_futurepharmacol4020022 crossref_primary_10_1016_j_ajo_2009_03_029 crossref_primary_10_1016_j_coph_2012_08_005 crossref_primary_10_1097_MD_0000000000020380 crossref_primary_10_1111_ceo_13336 crossref_primary_10_1111_j_1442_9071_2011_02563_x crossref_primary_10_1155_2017_4320408 crossref_primary_10_1038_cddis_2016_397 crossref_primary_10_1007_s10792_022_02603_z crossref_primary_10_3390_jpm12111884 crossref_primary_10_1016_j_exer_2011_04_002 crossref_primary_10_1167_iovs_19_27113 crossref_primary_10_1016_j_preteyeres_2020_100881 |
ContentType | Journal Article |
Copyright | Copyright 2003 British Journal of Ophthalmology 2004 INIST-CNRS COPYRIGHT 2003 BMJ Publishing Group Ltd. Copyright: 2003 Copyright 2003 British Journal of Ophthalmology Copyright © Copyright 2003 British Journal of Ophthalmology 2003 |
Copyright_xml | – notice: Copyright 2003 British Journal of Ophthalmology – notice: 2004 INIST-CNRS – notice: COPYRIGHT 2003 BMJ Publishing Group Ltd. – notice: Copyright: 2003 Copyright 2003 British Journal of Ophthalmology – notice: Copyright © Copyright 2003 British Journal of Ophthalmology 2003 |
DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR BTHHO CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.1136/bjo.87.12.1463 |
DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central BMJ Journals ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) BMJ Journals Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE ProQuest One Academic Middle East (New) |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1468-2079 |
EndPage | 1465 |
ExternalDocumentID | PMC1920576 4012344701 A111971630 14660453 15811123 10_1136_bjo_87_12_1463 ark_67375_NVC_7GCW607H_F bjophthalmol |
Genre | Comparative Study Clinical Trial Randomized Controlled Trial Journal Article |
GroupedDBID | --- -~X .55 .GJ .VT 0R~ 18M 23N 2WC 354 39C 3O- 4.4 40O 53G 5GY 5RE 5VS 6J9 7X7 7~S 88E 8FI 8FJ 8R4 8R5 AAHLL AAKAS AAOJX AAWJN ABAAH ABJNI ABKDF ABMQD ABTFR ABUWG ABVAJ ACCCW ACGFO ACGFS ACGTL ACHTP ACMFJ ACNCT ACOAB ACOFX ACQSR ACTZY ADBBV ADCEG ADZCM AENEX AFKRA AFWFF AGQPQ AHMBA AHNKE AHQMW AJYBZ ALIPV ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AZFZN BAWUL BENPR BLJBA BOMFT BPHCQ BTFSW BTHHO BVXVI C1A C45 CAG CCPQU COF CS3 CXRWF DIK DU5 E3Z EBS EJD F5P FYUFA H13 HAJ HMCUK HYE HZ~ IAO IEA IHR IOF ITC J5H KQ8 L7B M1P N9A NTWIH NXWIF O9- OK1 OVD P2P PHGZT PQQKQ PROAC PSQYO Q2X R53 RHI RMJ RPM RV8 TEORI TR2 UAW UKHRP UYXKK V24 VM9 W8F WH7 WOQ X7M XOL YFH YQY ZGI 3V. BSCLL RHF AAFWJ AAYXX ACQHZ AERUA CITATION PHGZM IQODW PJZUB PPXIY CGR CUY CVF ECM EIF NPM PMFND 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM |
ID | FETCH-LOGICAL-b593t-d1e26dccdeac3f5ff502dc5d931c728f408e5e73f826b2a6b9aae5862db9ff783 |
IEDL.DBID | 7X7 |
ISSN | 0007-1161 |
IngestDate | Thu Aug 21 14:11:27 EDT 2025 Thu Sep 04 16:27:09 EDT 2025 Fri Jul 25 05:15:14 EDT 2025 Fri Jun 13 00:49:10 EDT 2025 Tue Jun 10 21:26:32 EDT 2025 Thu Jan 02 23:03:59 EST 2025 Mon Jul 21 09:13:46 EDT 2025 Thu Apr 24 23:01:14 EDT 2025 Tue Jul 01 00:53:24 EDT 2025 Wed Oct 30 09:22:17 EDT 2024 Thu Apr 24 23:02:35 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Keywords | Antiglaucomatous agent Human α2-Adrenergic receptor Quinoxaline derivatives Therapy Open angle glaucoma Brimonidine Contrast Chemotherapy Sensitivity Treatment Primary α-Adrenergic receptor agonist |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b593t-d1e26dccdeac3f5ff502dc5d931c728f408e5e73f826b2a6b9aae5862db9ff783 |
Notes | ark:/67375/NVC-7GCW607H-F PMID:14660453 Correspondence to: Sarah L Hosking Neuroscience Research Institute, Aston University, Aston Triangle, Birmingham B4 7ET, UK; s.l.hosking@aston.ac.uk href:bjophthalmol-87-1463.pdf istex:4E9AA1558A582EB725B49362A05900CB4896D6B6 local:0871463 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 Correspondence to: Sarah L Hosking Neuroscience Research Institute, Aston University, Aston Triangle, Birmingham B4 7ET, UK; s.l.hosking@aston.ac.uk |
OpenAccessLink | https://bjo.bmj.com/content/bjophthalmol/87/12/1463.full.pdf |
PMID | 14660453 |
PQID | 1778903786 |
PQPubID | 2041039 |
PageCount | 3 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_1920576 proquest_miscellaneous_71436891 proquest_journals_1778903786 gale_infotracgeneralonefile_A111971630 gale_infotracacademiconefile_A111971630 pubmed_primary_14660453 pascalfrancis_primary_15811123 crossref_citationtrail_10_1136_bjo_87_12_1463 crossref_primary_10_1136_bjo_87_12_1463 istex_primary_ark_67375_NVC_7GCW607H_F bmj_primary_10_1136_bjo_87_12_1463 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2003-12-01 |
PublicationDateYYYYMMDD | 2003-12-01 |
PublicationDate_xml | – month: 12 year: 2003 text: 2003-12-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | BMA House, Tavistock Square, London, WC1H 9JR |
PublicationPlace_xml | – name: BMA House, Tavistock Square, London, WC1H 9JR – name: London – name: England |
PublicationTitle | British journal of ophthalmology |
PublicationTitleAlternate | Br J Ophthalmol |
PublicationYear | 2003 |
Publisher | BMJ Publishing Group Ltd BMJ BMJ Publishing Group LTD Copyright 2003 British Journal of Ophthalmology |
Publisher_xml | – name: BMJ Publishing Group Ltd – name: BMJ – name: BMJ Publishing Group LTD – name: Copyright 2003 British Journal of Ophthalmology |
SSID | ssj0002617 |
Score | 2.0019495 |
Snippet | Aims: To determine the visual outcome following initiation of brimonidine therapy in glaucoma. Methods: 16 newly diagnosed previously untreated glaucoma... To determine the visual outcome following initiation of brimonidine therapy in glaucoma. 16 newly diagnosed previously untreated glaucoma patients were... To determine the visual outcome following initiation of brimonidine therapy in glaucoma.AIMSTo determine the visual outcome following initiation of brimonidine... Aims: To determine the visual outcome following initiation of brimonidine therapy in glaucoma. Methods: 16 newly diagnosed previously untreated glaucoma... |
SourceID | pubmedcentral proquest gale pubmed pascalfrancis crossref istex bmj |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1463 |
SubjectTerms | Adrenergic alpha-Agonists - therapeutic use Adrenergic beta-Antagonists - therapeutic use Analysis of Variance Biological and medical sciences brimonidine Brimonidine Tartrate Care and treatment Clinical Science - Scientific Reports Contrast Sensitivity Defects Disease Drug dosages Eye Glaucoma Glaucoma, Open-Angle - drug therapy Glaucoma, Open-Angle - physiopathology Humans Intraocular Pressure - drug effects Investigations Medical sciences Middle Aged neuroprotection Ophthalmology Pharmacology. Drug treatments primary open angle glaucoma Quinoxalines - therapeutic use Receptors, Adrenergic, alpha-2 - drug effects Retina Retinopathies timolol Timolol - therapeutic use |
Title | Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection |
URI | http://bjo.bmj.com/content/87/12/1463.full https://api.istex.fr/ark:/67375/NVC-7GCW607H-F/fulltext.pdf https://www.ncbi.nlm.nih.gov/pubmed/14660453 https://www.proquest.com/docview/1778903786 https://www.proquest.com/docview/71436891 https://pubmed.ncbi.nlm.nih.gov/PMC1920576 |
Volume | 87 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1468-2079 dateEnd: 20051231 omitProxy: true ssIdentifier: ssj0002617 issn: 0007-1161 databaseCode: KQ8 dateStart: 19170101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1468-2079 dateEnd: 20071231 omitProxy: true ssIdentifier: ssj0002617 issn: 0007-1161 databaseCode: DIK dateStart: 19170101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1468-2079 dateEnd: 20071231 omitProxy: true ssIdentifier: ssj0002617 issn: 0007-1161 databaseCode: RPM dateStart: 19170101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1468-2079 dateEnd: 20250330 omitProxy: true ssIdentifier: ssj0002617 issn: 0007-1161 databaseCode: 7X7 dateStart: 19220101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1468-2079 dateEnd: 20250330 omitProxy: true ssIdentifier: ssj0002617 issn: 0007-1161 databaseCode: BENPR dateStart: 19220101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3db9MwELdglRAviG8Co1gIsaewJI4_ygsa1UqFtAohBn2zHNsZHSMdTSvx53OXuClBA55zck72-fzz3fl3hLwoVc5zn2OGtfBxnhkWG2ZGcZExbg3g68zi4-STmZie5u_nfB4CbnUoq9z6xMZRu6XFGPlhKvHJJpNKvLn8EWPXKMyuhhYa18kgBaiCVi3n3YWrYRtv4a-MU4A2gbQxZeKwOF--UhIjgeAqkDKw-H7eO5qCgx7gZP_EiklTw6SVbbeLq-Don1WVvx1Tk9vkVsCX9Kg1iDvkmq_ukhsnIYN-j6yQjmpl6jWtsXS97R1BF01owde0aRlOixWsYLWAY83T9oEWiFT0smWmoNhxi5rq7MJTAN8bmD_zmhpq4UCkgIFpw5EZCCBg2e-T08nxp_E0Dn0X4oKP2Dp2qc-Es9aBU2YlL0ueZM5yN2KplZkq80R57iUr4WpSZEYUI2M8h6uRKzACrNgDslctK_-IUPhYclVy7pzKywSFjE-Fy5H43SU2Is9h4nXQXzc3EiY0rI5WUqcZ3kxYROLtumgbmMuxgcbFX-UPOvn_jXyAy6xxM8OI1oQ3CaA80mLpoxSzrABZk4i87EmetaTgVwo2JtP92ay-YfGc5Hr2eazlu_EXkcipnkRk2LOpnapcwWgZKLe_NTIdHEutd9sgIs-6z-ASMM9jKr_c1Bpb2gs1SiPysLXI3dC5EIDhYWjZs9VOAMnG-1-qxdeGdBy2F0B78fjfSj0hN9tqR6z32Sd769XGPwXUti6GzdYcksHb49mHj78AG2xDrw |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGJgEviG8CY7MQsKdsSfyVIiE0FUrH1j5t0Dfj2M7WbaSjaQX8U_yN3CVpS9GApz37dLV6l_Pv7LvfEfI8T7ngnuMLa-ZDnhgWGmZaYZYwYQ3g68Ric3KvL7tH_MNADFbIz1kvDJZVzmJiFajdyOId-U6ssGWTqVS-ufga4tQofF2djdCo3WLf__gGKVv5eu8t2PdFknTeHba7YTNVIMxEi01CF_tEOmsdhByWizwXUeKscC0WW5WkOY9SL7xiOQDvLDEyaxnjBQB_l-H9ZspA7zWyxlnEkatfDeYJXsVuXsNtFcYApRqSyJjJnex0tJ0qvHmE0IQUhdmX06WjsDkQ1tC437FC05RgpLyernEZ_P2zivO3Y7Fzm9xq8CzdrR3wDlnxxV1yvde82N8jY6S_GptyQkssla9nVdBhdZXhS1qNKKfZGDymGMIx6mndEAYiBb2omTAoTviipjg-9xTA_hTsZV5RQy0cwBQwN604ORvCCXCz--ToSizygKwWo8I_IhQWc5HmQjiX8jxCIeNj6TgSzbvIBuQZ_PG62b-uMiAmNVhHp0rHCWZCLCDhzC7aNkzpOLDj_K_yW3P5_2neQjNrDB6g0ZqmBwI2jzRcejfGV12AyFFAXi5JHtck5JcKVi4z_2UzPsNiPSV0_2Nbq_ftTzJSXd0JyMaSTy22KlLQlsDm1mdOpptAVurFZxeQzfkyhCB8VzKFH01LrWIcY9CKA_Kw9siFai4l5AygWi356lwAyc2XV4rhSUVyDpkHpBLy8b83tUludA97B_pgr7__hNysKy2x1midrE7GU_8UEOMk26g-U0o-X3Vc-AXdvoEl |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGJk28IL4JjM1CwJ5CEzuOUySEpo7SMVbxwKBvnuPYo_tIR9MK-Nf467hL3JaiAU979ul66l3uw777HSFPXZaIxCb4wprbMGGah5rrdpgzLoyG_JoZHE4-6Ke9w-TdQAxWyM_ZLAy2Vc58Yu2oi5HBO_JWLHFkk8ssbTnfFvFht_v64muIG6TwpXW2TqMxkX374xuUb9WrvV3Q9TPGum8-dnqh3zAQ5qLNJ2ERW5YWxhTgfrgTzomIFUYUbR4byTKXRJkVVnIHSXjOdJq3tbYCioAix7vOjAPfa2RN8oRjO5kczIu9Gum8Sb1lGENa5QEjY5628pPRi0ziLSS4KYQrzM9PlsKiDw5rqOjv2K2pK1CYazZtXJYK_9nR-VuI7N4kN3xuS3caY7xFVmx5m6wf-Nf7O2SMUFhjXU1ohW3zzd4KOqyvNWxF63XlNB-D9ZRDCKmWNsNhQFLSiwYVg-K2L6rL4zNLIfGfgu70S6qpgWBMIf-mNT6nB58Ak7tLDq9EI_fIajkq7QNC4dCJzAlRFFniIiTSNk6LBEHni8gE5An88crLr-pqiKcKtKMyqWKGVREPSDjTizIeNR2Xd5z9lX57Tv8_ztuoZoWOBDga7echQHiE5FI7Mb7wQrocBeT5EuVxA0h-KWFtMvNf1uNTbNyTQvU_dZR82_mcRrKnugHZXLKphagiA24MhNuYGZnyTq1Si08wIFvzY3BH-MakSzuaVkrGuNKgHQfkfmORC9ZJmkL9AKzlkq3OCRDofPmkHH6pAc-hCoGyIn34b6G2yDp4BPV-r7__iFxvmi6x7WiDrE7GU_sYksdJvll_pZQcXbVb-AXXioVg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Contrast+sensitivity+improves+after+brimonidine+therapy+in+primary+open+angle+glaucoma%3A+a+case+for+neuroprotection&rft.jtitle=British+journal+of+ophthalmology&rft.au=Evans%2C+D+W&rft.au=Hosking%2C+S+L&rft.au=Gherghel%2C+D&rft.au=Bartlett%2C+J+D&rft.date=2003-12-01&rft.issn=0007-1161&rft.volume=87&rft.issue=12&rft.spage=1463&rft_id=info:doi/10.1136%2Fbjo.87.12.1463&rft_id=info%3Apmid%2F14660453&rft.externalDocID=14660453 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1161&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1161&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1161&client=summon |